中國生物官方微信公號消息

China Biological Official WeChat Public Account News

經國務院聯防聯控機制有關部門組織論證,國藥集團中國生物北京生物制品研究所的新冠病毒滅活疫苗獲批在3-17歲人群中緊急使用

According to the demonstration organized by the relevant departments of the Joint Prevention and Control Mechanism of the State Council, the new coronavirus inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group has been approved for emergency use in people aged 3-17

國藥集團中國生物新冠疫苗3-17歲年齡組已經在河南完成I/II期臨床試驗，3-17歲人群免后中和抗體陽轉率為100%，中和抗體GMT和陽轉率與成人組相比無顯著性差異，接種后安全性良好，不良反應主要為發熱和接種部位疼痛，嚴重程度以1級為主，未見嚴重不良反應，不良反應發生率隨接種劑次增加而逐漸降低

Sinopharm China Bio-New Crown Vaccine 3-17 years old age group has completed phase I/II clinical trials in Henan. After 3-17 years of age, the neutralizing antibody positive conversion rate is 100%, and the neutralizing antibody GMT and positive conversion rate is the same as that of adults There is no significant difference between the two groups. The safety after vaccination is good. The adverse reactions are mainly fever and pain at the inoculation site. The severity is mainly grade 1, and no serious adverse reactions are seen. The incidence of adverse reactions gradually decreases with the increase in the number of inoculations.

 

From website: https://my-h5news.app.xinhuanet.com/